XORTX Therapeutics (CVE:XRTX), (NASDAQ:XRTX) focuses on developing innovative therapies aimed at treating kidney disease and conditions that lead to kidney damage. It is traded on the NASDAQ stock exchange under the ticker symbol XRTX. The company is dedicated to advancing its clinical programs to address unmet medical needs in the treatment of progressive kidney disease. XORTX's projects primarily involve the development of therapeutic solutions that target the underlying causes of kidney damage, including high uric acid levels and oxidative stress. Their objective is to improve the quality of life for patients suffering from these debilitating conditions through the advancement of their research and development efforts. By leveraging its expertise in kidney health, XORTX is committed to bringing novel treatments to market that can offer hope and improved outcomes for patients facing kidney-related health challenges.